(Q35651392)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

review article

1 reference

title

WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

obsessive-compulsive disorder

18 November 2019

main subject

1 reference

6

David J Nutt

0 references

Donatella Marazziti

4

object named as

Donatella Marazziti

1 reference

9 August 2017

9

Joseph Zohar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

3

Eric Hollander

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

author name string

John H Greist

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Borwin Bandelow

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Stuart A Montgomery

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Ahmed Okasha

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Richard P Swinson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

World Council of Anxiety

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Donatella Marazziti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

David J Nutt

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

issue

8 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

page(s)

7-16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group

18 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Current concepts in the pharmacological treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Psychiatric disorders in relatives of probands with obsessive—compulsive disorder and co-morbid major depression or generalized anxiety

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Possible role of neuropeptides in obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Clomipramine in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Refining treatment approaches in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Modification of expectations in cases with obsessional rituals

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Long-term management of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Behavioral, cognitive, and family therapy for obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Citalopram in refractory obsessive-compulsive disorder: an open study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Recent developments in the psychopharmacology of anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

A maintenance program for obsessive-compulsive disorder using exposure with response prevention: 2-year follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006908

7 January 2021

10.1017/S1092852900006908

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14767394%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference